Pharmaceuticals Global On demand · 24-48h

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Strategic Research Report

Global CD73 and DDR1-Targeted Drugs for Digestive System Tum…
$3,500 USD
Market Research Reports
Strategic Research Report
Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market
$2332025
9.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: CD73 Target, DDR1 Target

By Application: Diagnosis, Therapeutics

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Arcus Biosciences / Gilead Sciences, AstraZeneca, Akeso, TJ Bio, I-Mab Biopharma, Innate Pharma, Phanes Therapeutics, Incyte Corp

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 82 pages
Market size 2025
$233
Million USD
Forecast CAGR
9.3%
2025-2032
Forecast 2032
$434.2
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market size is predicted to grow from US$ 233 million in 2025 to US$ 422 million in 2032; it is expected to grow at a CAGR of 9.3% from 2026 to 2032.

CD73- and DDR1-targeted drugs for digestive system tumors are therapeutic or diagnostic agents designed to selectively bind to or inhibit CD73 or discoidin domain receptor 1 (DDR1), two proteins involved in tumor growth, immune evasion, stromal remodeling, invasion and treatment resistance in gastrointestinal cancers.

CD73-targeted drugs act against ecto-5′-nucleotidase, an enzyme that converts extracellular AMP into immunosuppressive adenosine. By blocking CD73 or using CD73 as a tumor-associated imaging target, these agents aim to reduce adenosine-mediated immune suppression, improve antitumor immune responses and identify CD73-expressing lesions.

DDR1-targeted drugs act against a collagen-activated receptor tyrosine kinase that regulates tumor–stroma interactions, extracellular-matrix signaling, cancer-cell migration and fibrotic barriers. Inhibiting or targeting DDR1 may reduce tumor invasion, improve immune-cell penetration and enhance drug delivery.

This report presents a comprehensive overview of the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • CD73 Target
  • DDR1 Target

Segment by Nucleoside

  • 68Ga
  • 18F
  • Lu177

Segment by Indications

  • Gastric Cancer
  • Colorectal Cancer
  • Pancreatic Cancer

Segment by players, this report covers

  • Arcus Biosciences / Gilead Sciences
  • AstraZeneca
  • Akeso
  • TJ Bio
  • I-Mab Biopharma
  • Innate Pharma
  • Phanes Therapeutics
  • Incyte Corp

Segment by Application

  • Diagnosis
  • Therapeutics

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Diagnosis, Therapeutics evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$233
2025
Forecast
$434.2
2032
CAGR
9.3%
2025–2032
Régions
5
global
Key companies
Arcus Biosciences / Gilead SciencesAstraZenecaAkesoTJ BioI-Mab BiopharmaInnate PharmaPhanes TherapeuticsIncyte Corp
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
CD73 TargetDDR1 Target
By Application
DiagnosisTherapeutics

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 CD73 Target
  • 3.1.3 DDR1 Target
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Diagnosis
  • 4.1.3 Therapeutics
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Arcus Biosciences / Gilead Sciences
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 AstraZeneca
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Akeso
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 TJ Bio
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 I-Mab Biopharma
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Innate Pharma
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Phanes Therapeutics
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Incyte Corp
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market size?
The global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market is estimated at US$ 233 million in 2025 (base year) and is projected to reach US$ 422 million by 2032.
What growth rate is expected for the CD73 and DDR1-Targeted Drugs for Digestive System Tumors market through 2032?
The market is expected to grow at a CAGR of 9.3% from 2026 to 2032, expanding from US$ 233 million in 2025 to US$ 422 million in 2032, roughly 1.8 times its base-year value.
How is CD73 and DDR1-Targeted Drugs for Digestive System Tumors defined?
CD73- and DDR1-targeted drugs for digestive system tumors are therapeutic or diagnostic agents designed to selectively bind to or inhibit CD73 or discoidin domain receptor 1 (DDR1), two proteins involved in tumor growth, immune evasion, stromal remodeling, invasion and treatment resistance in gastrointestinal cancers.
What are the main segments of the CD73 and DDR1-Targeted Drugs for Digestive System Tumors market by type?
By type, the market is segmented into CD73 Target and DDR1 Target.
Which applications drive demand in the CD73 and DDR1-Targeted Drugs for Digestive System Tumors market?
Key applications covered include Diagnosis and Therapeutics.
Who are the key players in the CD73 and DDR1-Targeted Drugs for Digestive System Tumors market?
Key players profiled include Arcus Biosciences / Gilead Sciences, AstraZeneca, Akeso, TJ Bio, I-Mab Biopharma, Innate Pharma, Phanes Therapeutics and Incyte Corp.
Which regions and countries are covered for CD73 and DDR1-Targeted Drugs for Digestive System Tumors?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What challenges does the CD73 and DDR1-Targeted Drugs for Digestive System Tumors market face?
DDR1-targeted drugs act against a collagen-activated receptor tyrosine kinase that regulates tumor–stroma interactions, extracellular-matrix signaling, cancer-cell migration and fibrotic barriers.
Who should buy the CD73 and DDR1-Targeted Drugs for Digestive System Tumors market report?
The report is intended for manufacturers and solution providers, distributors and end users in Diagnosis and Therapeutics, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the CD73 and DDR1-Targeted Drugs for Digestive System Tumors market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.